0000899243-20-018268.txt : 20200702
0000899243-20-018268.hdr.sgml : 20200702
20200702160839
ACCESSION NUMBER: 0000899243-20-018268
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200630
FILED AS OF DATE: 20200702
DATE AS OF CHANGE: 20200702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Spellman David A
CENTRAL INDEX KEY: 0001733204
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 201009345
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-30
0
0001517022
Akebia Therapeutics, Inc.
AKBA
0001733204
Spellman David A
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST STREET
CAMBRIDGE
MA
02142
0
1
0
0
SVP, CFO and Treasurer
Employee Stock Option (Right to buy)
13.58
2020-06-30
4
A
0
280000
0.00
A
2030-06-30
Common
Stock
280000
280000
D
The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest
over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.
/s/ Nicole R. Hadas, attorney-in-fact for David A. Spellman
2020-07-02